NLM Digital Collections

Search

Start Over Subjects Insurance, Pharmaceutical Services -- economics ✖Remove constraint Subjects: Insurance, Pharmaceutical Services -- economics

1. State Pharmacy Assistance Programs vs. Medicare prescription drug plans: how do they contain rising costs?

Publication:
[Washington, D.C.] : AcademyHealth, [2005]
Subject(s):
Cost Control
Medicare -- economics
State Health Plans -- economics
Cost Sharing
Drug Costs
Drug Utilization Review
Drugs, Generic
Fees, Pharmaceutical
Formularies as Topic
Insurance Coverage -- legislation & jurisprudence
Insurance, Pharmaceutical Services -- economics
Insurance, Pharmaceutical Services -- legislation & jurisprudence
Medicare -- legislation & jurisprudence
Humans
United States

3. Excluding noncovered versions when setting payment for two Part B drugs would have resulted in lower drug costs for Medicare and its beneficiaries

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, November 2017
Subject(s):
Drug Costs
Insurance, Pharmaceutical Services -- economics
Medicare Part B -- economics
Prospective Payment System
Abatacept -- economics
Certolizumab Pegol -- economics
Cost Savings
Injections -- economics
Self Care -- economics
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)
Healthcare common procedure coding system

5. Impact of Medicare Advantage prescription drug plan star ratings on enrollment before and after implementation of quality-related bonus payments in 2012

Author(s):
Li, Pengxiang, author
Doshi, Jalpa A., author
Publication:
Philadelphia, PA : Leonard Davis Institute of Health Economics, May 2016
Subject(s):
Insurance, Pharmaceutical Services -- economics
Medicare Part C -- economics
Medicare Part C -- utilization
Quality of Health Care
Reimbursement, Incentive
Longitudinal Studies
Medicare Part D -- economics
Humans
United States
Centers for Medicare & Medicaid Services (U.S.)

6. Abuse-deterrent formulations of opioids: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, August 8, 2017
Subject(s):
Abuse-Deterrent Formulations -- economics
Abuse-Deterrent Formulations -- statistics & numerical data
Analgesics, Opioid -- economics
Analgesics, Opioid -- therapeutic use
Opioid-Related Disorders -- economics
Opioid-Related Disorders -- prevention & control
Prescription Drug Diversion -- statistics & numerical data
Comparative Effectiveness Research
Cost-Benefit Analysis
Delayed-Action Preparations -- economics
Delayed-Action Preparations -- therapeutic use
Drug Compounding -- economics
Drug Overdose -- mortality
Insurance Coverage -- economics
Insurance, Pharmaceutical Services -- economics
Opioid-Related Disorders -- epidemiology
Humans
United States

8. Short-term limited duration plans and HIV

Author(s):
Dawson, Lindsey, author
Kates, Jennifer, author
Publication:
San Francisco, CA : Henry J. Kaiser Family Foundation, June 2018
Subject(s):
HIV Infections -- economics
Insurance Benefits -- economics
Insurance Coverage -- economics
Insurance, Health -- economics
Cost Sharing
Health Services Accessibility -- economics
Insurance Benefits -- statistics & numerical data
Insurance Coverage -- statistics & numerical data
Insurance, Health -- statistics & numerical data
Insurance, Pharmaceutical Services -- economics
Humans
United States

9. Medicare Part D: a first look at prescription drug plans in 2019

Author(s):
Cubanski, Juliette, author
Damico, Anthony, author
Neuman, Tricia, author
Publication:
San Francisco, CA : Henry J. Kaiser Family Foundation, October 2018
Subject(s):
Medicare Part D -- economics
Medicare Part D -- statistics & numerical data
Cost Sharing
Deductibles and Coinsurance
Insurance Benefits
Insurance, Pharmaceutical Services -- economics
Insurance, Pharmaceutical Services -- statistics & numerical data
Humans
United States